CYP2B6*6 is associated with increased breast cancer risk

Autor: Justenhoven, Christina, Pentimalli, Daniela, Rabstein, Sylvia, Harth, Volker, Lotz, Anne, Pesch, Beate, Brüning, Thomas, Dörk, Thilo, Schürmann, Peter, Bogdanova, Natalia, Park-Simon, Tjoung-Won, Couch, Fergus J., Olson, Janet E., Fasching, Peter A, Beckmann, Matthias W., Häberle, Lothar, Ekici, Arif, Hall, Per, Czene, Kamilla, Liu, Janjun, Li, Jingmei, Baisch, Christian, Hamann, Ute, Ko, Yon-Dschun, Brauch, Hiltrud
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Zdroj: International Journal of Cancer
International Journal of Cancer; Vol 134
ISSN: 0020-7136
DOI: 10.1002/ijc.28356
Popis: The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) assay. The GENICA breast cancer case-control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.
Databáze: OpenAIRE
Externí odkaz: